ArticlePloS one2017
Development of topical ophthalmic In Situ gel-forming estradiol delivery system intended for the prevention of age-related cataracts.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 68 citations in OpenAlex.
- Article
- Protective Effects of Estradiol on Disease Progression in a Murine Model of Fuchs Endothelial Corneal Dystrophy.Investigative ophthalmology & visual science · 2025Article
- Optimized Ion-Sensitive Hydrogels Based on Gellan Gum and Arabinogalactan for the Treatment of Dry Eye Disease.Gels (Basel, Switzerland) · 2025Article
- Article
- Hydrogels for Mucosal Drug Delivery.ACS applied bio materials · 2023Review
- Cationic Nano-Lipidic Carrier Mediated Ocular Delivery of Triamcinolone Acetonide: A Preclinical Investigation in the Management of Uveitis.Life (Basel, Switzerland) · 2023Article
- Caspofungin-Loaded Formulations for Treating Ocular Infections Caused byGels (Basel, Switzerland) · 2023Article
- Gellan gum-based in situ gelling ophthalmic nanosuspension of Posaconazole.Drug delivery and translational research · 2022Article
- Article
- Nanoparticles Loaded Thermoresponsive In Situ Gel for Ocular Antibiotic Delivery against Bacterial Keratitis.Polymers · 2022Article
- New Preservative-Free Formulation for the Enhanced Ocular Bioavailability of Prostaglandin Analogues in Glaucoma.Pharmaceutics · 2022Article
- Gel-Based Materials for Ophthalmic Drug Delivery.Gels (Basel, Switzerland) · 2021Review
- Ion-Triggered In Situ Gelling Nanoemulgel as a Platform for Nose-to-Brain Delivery of Small Lipophilic Molecules.Pharmaceutics · 2021Article
- Ciprofloxacin self-dissolvable Soluplus based polymeric films: a novel proposal to improve the management of eye infections.Drug delivery and translational research · 2021Article
- Combination of Nanomicellar Technology and In Situ Gelling Polymer as Ocular Drug Delivery System (ODDS) for Cyclosporine-A.Pharmaceutics · 2021Article
- Evaluation ofBioImpacts : BI · 2021Article
- Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections.PloS one · 2021Article
- Article
- Preparation and characterization of bear bile-loaded pH sensitiveIranian journal of basic medical sciences · 2020Article
- Design of l-Lysine-Based Organogelators and Their Applications in Drug Release Processes.ACS omega · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of this study was to develop and characterize an ion-activated in situ gel-forming estradiol (E2) solution eye drops intended for the prevention of age-related cataracts. Accordingly, in situ gelling eye drops were made using gellan gum as an ion-activated gel-forming polymer, polysorbate-80 as drug solubilizing agent, mannitol as tonicity agent, and combination of potassium sorbate and edetate disodium dihydrate (EDTA) as preservatives. The formulations were tested for the following characteristics: pH, clarity, osmolality, antimicrobial efficacy, rheological behavior, and in vitro drug release. Stability of the formulation was also monitored for 6 months at multiple storage conditions per ICH Q1A (R2) guidelines. The solution eye drops resulted in an in-situ phase change to gel-state when mixed with simulated tear fluid (STF). The gel structure formation was confirmed by viscoelastic measurements. Drug release from the gel followed non-fickian mechanism with 80% of drug released in 8 hr. The formulations were found to be clear, isotonic with suitable pH and viscoelastic behavior and stable at accelerated and long-term storage conditions for 6 months. In vitro results suggest that the developed formulation is suitable for further investigation in animal models to elucidate the ability of estrogen to prevent and delay cataracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.